Page last updated: 2024-12-06

hrp 112

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CycloProvera: contains medroxyprogesterone acetate & estradiol cypionate; contains 25 mg medroxyprogesterone acetate and 5 mg estradiol-cypionate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62995
MeSH IDM0106385

Synonyms (10)

Synonym
lunelle
71615-27-5
hrp 112
cycloprovera
hrp112
pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6-alpha)-, mixt. with (17-beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl cyclopentanepropanoate
cyclofem
3-hydroxyestra-1(10),2,4-trien-17-yl 3-cyclopentylpropanoate--6-methyl-3,20-dioxopregn-4-en-17-yl acetate (1/1)
DTXSID40992177
[(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclo

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives."( Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lu
Cromie, MA; Garceau, RJ; Kaunitz, AM, 1999
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
" While the results from all centres indicated that the four preparations were all effective in inhibiting ovulation for at least one month, there were marked between centre differences in pharmacokinetic profiles."( A multicentered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and of DepoProvera. World Health Organization Task Force on Long-acting Systemic Agents for Fertility Regulation.
Garza-Flores, J; Hall, PE; Koloszar, S; Konsayreepong, R; Kovacs, L; Perez-Palacios, G; Rodriguez, V; Tang-Keow, P; Virutamasen, P, 1987
)
0.27
"To provide pharmacokinetic data for a safety evaluation of long-term use of the monthly injectable Cyclofem (25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate), 9 fertile Chinese women 27-34 years of age were enrolled in a 12-month clinical study."( Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women.
Han, XJ; Sang, GW; Shao, QX; Weng, LJ; Zhou, XF, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks (serum progesterone concentrations did not exceed 1 ng/mL)."( Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
Rahimy, MH; Ryan, KK, 1999
)
0.3
" Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks."( Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
Rahimy, MH; Ryan, KK, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (9.52)18.7374
1990's36 (57.14)18.2507
2000's20 (31.75)29.6817
2010's1 (1.59)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.41 (24.57)
Research Supply Index4.61 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials32 (47.76%)5.53%
Reviews17 (25.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (26.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]